[1]栾学冰.重组人尿激酶原对ST段抬高型AMI患者血浆纤溶因子及血管再通的影响[J].医学信息,2020,33(13):156-157.[doi:10.3969/j.issn.1006-1959.2020.13.047]
　LUAN Xue-bing.Effect of Recombinant Human Prourokinase on Plasma Fibrinolytic Factor and Vascular Recanalization in Patients with ST-segment Elevation AMI[J].Medical Information,2020,33(13):156-157.[doi:10.3969/j.issn.1006-1959.2020.13.047]
点击复制

重组人尿激酶原对ST段抬高型AMI患者血浆纤溶因子及血管再通的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
156-157
栏目:
药物与临床
出版日期:
2020-07-01

文章信息/Info

Title:
Effect of Recombinant Human Prourokinase on Plasma Fibrinolytic Factor and Vascular Recanalization in Patients with ST-segment Elevation AMI
文章编号:
1006-1959（2020）13-0156-02
作者:
栾学冰
（佳木斯市中心医院心内科，黑龙江 佳木斯 154002）
Author(s):
LUAN Xue-bing
(Department of Cardiology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
重组人尿激酶原; 急性心肌梗死; 血浆纤溶因子; 血管再通率
Keywords:
Recombinant human prourokinase; Acute myocardial infarction; Plasma fibrinolytic factor; Revascularization rate
分类号:
R542.2+2
DOI:
10.3969/j.issn.1006-1959.2020.13.047
文献标志码:
A
摘要:
目的 研究重组人尿激酶原对ST段抬高型急性心肌梗死（AMI）患者血浆纤溶因子及血管再通的影响。方法 选取2018年9月~2019年9月在我院诊治的106例ST段抬高型AMI患者为研究对象，采用随机数字表法分为对照组和观察组，各53例。对照组采用尿激酶治疗，观察组采用重组人尿激酶原治疗，比较两组临床血管再通率、治疗前后血浆纤溶因子指标[人组织纤溶酶原激活物（t-PA）、人纤溶酶原激活物抑制剂（PAI-1）]水平、ST段完全回落率、心脏事件和出血发生率及临床不良反应发生情况。结果 观察组血管再通率为81.13%，高于对照组的67.92%（P＜0.05）；治疗后两组t-PA均高于治疗前，观察组高于对照组（P＜0.05）；治疗后两组PAI-1均低于治疗前，PAI-1低于对照组（P＜0.05）；观察组ST段完全回落率高于对照组，心脏事件和出血发生率均低于对照组（P＜0.05）；观察组不良反应总发生率为7.54%，低于对照组的16.98%（P＜0.05）。结论 重组人尿激酶原可提高ST段抬高型AMI血管再通率，促进血浆纤溶因子水平改善，提升ST段完全回落率，降低心脏事件和出血发生率，且不良反应少，安全性良好。
Abstract:
Objective To study the effect of recombinant human urokinase on plasma fibrinolytic factor and vascular recanalization in patients with ST-segment elevation acute myocardial infarction (AMI).Methods A total of 106 patients with ST-segment elevation AMI diagnosed and treated in our hospital from September 2018 to September 2019 were selected as the research object. They were divided into a control group and an observation group with a random number table method, each with 53 cases. The control group was treated with urokinase, and the observation group was treated with recombinant human urokinase. The clinical vascular recanalization rate, plasma fibrinolytic factor index before and after treatment were compared between the two groups [human tissue plasminogen activator (t-PA), human fibrinogen Plasminogen activator inhibitor (PAI-1)] level, ST segment complete fall rate, heart event and bleeding rate, and clinical adverse reactions.Results The recanalization rate of the observation group was 81.13%, which was higher than 67.92% of the control group (P＜0.05); after treatment, the t-PA of both groups was higher than before treatment, and the observation group was higher than the control group (P＜0.05); after treatment PAI-1 in both groups was lower than before treatment, and PAI-1 was lower than the control group (P＜0.05); the rate of complete ST segment fallback in the observation group was higher than that in the control group, and the incidence of cardiac events and bleeding was lower than that in the control group (P＜0.05).The total incidence of adverse reactions in the observation group was 7.54%, lower than 16.98% in the control group (P＜0.05).Conclusion Recombinant human prourokinase can increase the vascular recanalization rate of ST-segment elevation AMI, promote the improvement of plasma fibrinolytic factor level, increase the ST-segment complete fall rate, reduce the incidence of cardiac events and bleeding, and have fewer adverse reactions and good safety.

参考文献/References:

[1]陈湾湾,姚朱华,马梅,等.溶栓后PCI与pPCI治疗急性ST段抬高型心肌梗死的效果观察[J].天津医药,2015,43(12):1-5.[2]王晋华.重组人尿激酶原在急性ST段抬高型心肌梗死中应用的疗效评价[J].中国现代药物应用,2016,10(16):201-202.[3]宋志平,杜丹阳,黄平,等.急性心肌梗死患者采用重组人尿激酶原溶栓治疗的疗效及安全性分析[J].临床医学工程,2014,4(21):469-470.[4]张春龙,彭绪东.重组人尿激酶原治疗急性ST段抬高型心肌梗死患者的临床研究[J].心肺血管病杂志,2017,36(6):436-439.

相似文献/References:

[1]郭建华.丹参川芎嗪联合阿托伐他汀钙治疗急性心肌梗死的疗效观察[J].医学信息,2018,31(01):145.[doi:10.3969/j.issn.1006-1959.2018.01.056]
　GUO Jian-hua.Effect of Salvia Miltiorrhiza Tetramethylpyrazine Combined with Atorvastatin Calcium in the Treatment of Acute Myocardial Infarction[J].Medical Information,2018,31(13):145.[doi:10.3969/j.issn.1006-1959.2018.01.056]
[2]余湘宁,赵献明.ECMO在危重症心脏疾病中的应用研究[J].医学信息,2018,31(04):38.[doi:10.3969/j.issn.1006-1959.2018.04.013]
　YU Xiang-ning,ZHAO Xian-ming.Study on the Application of ECMO in Critical Heart Disease[J].Medical Information,2018,31(13):38.[doi:10.3969/j.issn.1006-1959.2018.04.013]
[3]何 丽.应激性高血糖与急性心肌梗死的机制研究[J].医学信息,2022,35(10):74.[doi:10.3969/j.issn.1006-1959.2022.10.018]
　HE Li.Mechanism of Stress Hyperglycemia and Acute Myocardial Infarction[J].Medical Information,2022,35(13):74.[doi:10.3969/j.issn.1006-1959.2022.10.018]
[4]宋俊燕,张 毅.重组人尿激酶原在急性ST段抬高型心肌梗死中的 疗效及并发症分析[J].医学信息,2018,31(11):133.[doi:10.3969/j.issn.1006-1959.2018.11.042]
　SONG Jun-yan,ZHANG Yi.Therapeutic Efficacy and Complications of Recombinant Human Pro-urokinase in Acute ST-elevation Myocardial Infarction[J].Medical Information,2018,31(13):133.[doi:10.3969/j.issn.1006-1959.2018.11.042]
[5]毛红岩,宁国贤.冠脉介入治疗对冠心病急性心肌梗死患者 心肌损伤及心室重塑的影响[J].医学信息,2018,31(12):102.[doi:10.3969/j.issn.1006-1959.2018.12.031]
　MAO Hong-yan,NING Guo-xian.Effects of Coronary Intervention on Myocardial Injury and Ventricular Remodeling in Patients with Coronary Heart Disease and Acute Myocardial Infarction[J].Medical Information,2018,31(13):102.[doi:10.3969/j.issn.1006-1959.2018.12.031]
[6]雷 锐,李 志.冠状动脉介入及替罗非班治疗老年急性心肌梗死并 心源性休克的疗效分析[J].医学信息,2018,31(14):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
　LEI Rui,LI Zhi.Effect of Coronary Intervention and Tirofiban on Elderly Patients with Acute Myocardial Infarction and Cardiogenic Shock[J].Medical Information,2018,31(13):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
[7]高 鹏,林文华,敬 锐,等.红细胞压积变化对急性ST段抬高型心肌梗死患者临床预后的影响[J].医学信息,2019,32(03):78.[doi:10.3969/j.issn.1006-1959.2019.03.024]
　GAO Peng,LIN Wen-hua,JING Rui,et al.Effect of Hematocrit Changes on Clinical Prognosis in Patients with Acute ST-segment Elevation Myocardial Infarction[J].Medical Information,2019,32(13):78.[doi:10.3969/j.issn.1006-1959.2019.03.024]
[8]高 珍,刘重斌,张菊英.氧疗对急性心肌梗死患者预后的影响[J].医学信息,2018,31(18):29.[doi:10.3969/j.issn.1006-1959.2018.18.011]
　GAO Zhen,LIU Chong-bin,ZHANG Ju-ying.Effect of Oxygenic Therapy on Prognosis of Patients with Acute Myocardial Infarction[J].Medical Information,2018,31(13):29.[doi:10.3969/j.issn.1006-1959.2018.18.011]
[9]韩 宇,朱丽丽,孙 婷,等.急性心肌梗死患者排便意愿的调查研究[J].医学信息,2018,31(20):111.[doi:10.3969/j.issn.1006-1959.2018.20.033]
　HAN Yu,ZHU Li-li,SUN Ting,et al.Investigation of Defecation Intention in Patients with Acute Myocardial Infarction[J].Medical Information,2018,31(13):111.[doi:10.3969/j.issn.1006-1959.2018.20.033]
[10]陈笑玲.急救护理流程再造在急性心肌梗死急诊介入治疗中的作用观察[J].医学信息,2018,31(23):168.[doi:10.3969/j.issn.1006-1959.2018.23.049]
　CHEN Xiao-ling.Effect of Emergency Nursing Process Reengineering on Emergency Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Medical Information,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.23.049]

更新日期/Last Update: 1900-01-01